Hunan Kelun Pharmaceutical
Clinical trials sponsored by Hunan Kelun Pharmaceutical, explained in plain language.
Hunan Kelun Pharmaceutical is a Chinese pharmaceutical company producing generic and innovative drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Healthy volunteers needed to test safety of experimental drug KLA478 Results expected Sep 2026 (estimated)
- New sedative candidate goes Head-to-Head with propofol in early human test Results expected Nov 2026 (estimated)
-
New painkiller combo under study: could it improve chronic pain treatment?
Disease control CompletedThis trial investigates how a new experimental drug called KL0011034 interacts with alfentanil, a strong opioid painkiller, in adults with moderate-to-severe chronic pain. The study measures how the drugs affect each other's levels in the body and monitors safety. Participants re…
Phase 1 • Sponsor: Hunan Kelun Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Generic cancer drug shows promise in small bioequivalence study
Knowledge-focused CompletedThis study tested whether a generic gefitinib tablet (made by Hunan Kelun) works the same as the brand-name drug Iressa in 38 healthy Chinese men. Each participant took a single dose of either the generic or brand-name drug after a meal, then switched to the other. Researchers me…
Phase 1 • Sponsor: Hunan Kelun Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Healthy men test generic vs. brand drug in fasting study
Knowledge-focused CompletedThis study tested whether a generic gefitinib tablet works the same as the brand-name version (Iressa) in the body. It involved 38 healthy Chinese men who took a single dose of each under fasting conditions. The goal was to check if the two drugs are bioequivalent, meaning they p…
Phase 1 • Sponsor: Hunan Kelun Pharmaceutical Co., Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC